According to the novel guidelines of the National Institute on Aging and Alzheimer's Association (NIA-AA) [4], the term Alzheimer's disease refers to patients with diagnosed Aβ plaques and tau deposits, detected in vivo by abnormal biomarkers of Aβ, and pathologic tau or postmortem examination. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.